Staurengo-Ferrari Larissa, Mizokami Sandra S, Fattori Victor, Silva Jean J, Zanichelli Patrícia G, Georgetti Sandra R, Baracat Marcela M, da França Luiz G, Pavanelli Wander R, Casagrande Rubia, Verri Waldiceu A
Departamento de Ciências Patológicas, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM480 PR445, CEP 86057-970, Cx Postal 10.011, Londrina, Paraná, Brazil.
Naunyn Schmiedebergs Arch Pharmacol. 2014 Nov;387(11):1053-68. doi: 10.1007/s00210-014-1030-0. Epub 2014 Aug 13.
Nitric oxide plays an important role in various biological processes including antinociception. The control of its local concentration is crucial for obtaining the desired effect and can be achieved with exogenous nitric oxide-carriers such as ruthenium complexes. Therefore, we evaluated the analgesic effect and mechanism of action of the ruthenium nitric oxide donor [Ru(HEDTA)NO] focusing on the role of cytokines, oxidative stress and activation of the cyclic guanosine monophosphate/protein kinase G/ATP-sensitive potassium channel signaling pathway. It was observed that [Ru(HEDTA)NO] inhibited in a dose-dependent (1-10 mg/kg) manner the acetic acid-induced writhing response. At the dose of 1 mg/kg, [Ru(HEDTA)NO] inhibited the phenyl-p-benzoquinone-induced writhing response, and formalin- and complete Freund's adjuvant-induced licking and flinching responses. Systemic and local treatments with [Ru(HEDTA)NO] also inhibited the carrageenin-induced mechanical hyperalgesia and increase of myeloperoxidase activity in paw skin samples. Mechanistically, [Ru(HEDTA)NO] inhibited carrageenin-induced production of the hyperalgesic cytokines tumor necrosis factor-α and interleukin-1β, and decrease of reduced glutathione levels. Furthermore, the inhibitory effect of [Ru(HEDTA)NO] in the carrageenin-induced hyperalgesia and myeloperoxidase activity was prevented by the treatment with ODQ (soluble guanylyl cyclase inhibitor), KT5823 (protein kinase G inhibitor) and glybenclamide (ATP-sensitive potassium channel inhibitor), indicating that [Ru(HEDTA)NO] inhibits inflammatory hyperalgesia by activating the cyclic guanosine monophosphate/protein kinase G/ATP-sensitive potassium channel signaling pathway, respectively. These results demonstrate that [Ru(HEDTA)NO] exerts its analgesic effect in inflammation by inhibiting pro-nociceptive cytokine production, oxidative imbalance and activation of the nitric oxide/cyclic guanosine monophosphate/protein kinase G/ATP-sensitive potassium channel signaling pathway in mice.
一氧化氮在包括抗伤害感受在内的各种生物过程中发挥着重要作用。控制其局部浓度对于获得预期效果至关重要,这可以通过外源性一氧化氮载体如钌配合物来实现。因此,我们评估了钌一氧化氮供体[Ru(HEDTA)NO]的镇痛作用及其作用机制,重点关注细胞因子、氧化应激以及环磷酸鸟苷/蛋白激酶G/ATP敏感性钾通道信号通路的激活所起的作用。结果发现,[Ru(HEDTA)NO]以剂量依赖性(1 - 10 mg/kg)方式抑制乙酸诱导的扭体反应。在1 mg/kg剂量下,[Ru(HEDTA)NO]抑制苯醌诱导的扭体反应以及福尔马林和完全弗氏佐剂诱导的舔舐和缩足反应。[Ru(HEDTA)NO]的全身和局部治疗也抑制了角叉菜胶诱导的机械性痛觉过敏以及爪垫皮肤样本中髓过氧化物酶活性的增加。从机制上讲,[Ru(HEDTA)NO]抑制角叉菜胶诱导的促痛细胞因子肿瘤坏死因子-α和白细胞介素-1β的产生以及还原型谷胱甘肽水平的降低。此外,用ODQ(可溶性鸟苷酸环化酶抑制剂)、KT5823(蛋白激酶G抑制剂)和格列本脲(ATP敏感性钾通道抑制剂)处理可阻止[Ru(HEDTA)NO]对角叉菜胶诱导的痛觉过敏和髓过氧化物酶活性的抑制作用,这表明[Ru(HEDTA)NO]分别通过激活环磷酸鸟苷/蛋白激酶G/ATP敏感性钾通道信号通路来抑制炎症性痛觉过敏。这些结果表明,[Ru(HEDTA)NO]通过抑制小鼠中促伤害感受性细胞因子的产生、氧化失衡以及一氧化氮/环磷酸鸟苷/蛋白激酶G/ATP敏感性钾通道信号通路的激活,在炎症中发挥其镇痛作用。